Search

everythinglearnresearchcommunity

for

Search:↓

Geriatric Julia Creek dunnarts often suffer from reproductive and skin diseases, impacting conservation efforts.

Treat pattern hair loss with finasteride and topical minoxidil.

Blocking 11β-HSD1 can lessen the harmful effects of glucocorticoids on hair growth cells.

Benzodiazepines changed hormone levels but did not affect hair growth in women with idiopathic hirsutism.

Flibanserin's effectiveness for low sexual desire in premenopausal women may vary based on hormone levels, with normal hormone levels showing better responses.

Hirsutism is more linked to high androgen levels than acne or hair loss, and a mix of hormonal tests is best for diagnosis; certain treatments can reduce symptoms.

The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.

Glucocorticoids are powerful anti-inflammatory drugs that must be used carefully to avoid serious side effects.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

A man with X-ALD improved after treatment, highlighting the need to consider X-ALD in similar patients and test their relatives.

The guide helps clinicians diagnose and manage hair loss, detailing examination techniques and treatments for different types of alopecia.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

The conclusion is that young women with excessive hair growth should be quickly tested for hormonal issues and treated to improve their social well-being.

The man's fatigue and erectile dysfunction were improved by treating his obesity-related low testosterone without needing testosterone replacement.

New treatments for low male hormones improved sexual function and mood but had unclear risks, especially for older men.

Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

South Asian women with PCOS are more likely to have metabolic issues and central obesity, and simple measures like waist size and blood pressure can help identify these risks early.

Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.

Testosterone therapy can help women with androgen deficiency by improving energy, sex drive, and bone health with few side effects.

Some women with acne have higher levels of free testosterone, which might suggest using hormonal treatments for acne.

Men with early hair loss may have higher insulin resistance and should be checked for related health issues.

Hormone imbalances can cause skin diseases, and understanding these links is important for diagnosis and treatment.

Most women with hirsutism or androgenic alopecia had polycystic ovaries, especially if they had irregular periods.

The document concluded that more research is needed to understand how estrogen affects the enzyme involved in hirsutism development.

Testosterone replacement may help postmenopausal women with sexual function and bone density, but suitable treatments are limited.

Spironolactone may cause sexual pain and arousal issues in women, which can improve after stopping the drug and using hormone cream.

Woman's hair loss diagnosis changed from CTE to AA; multiple biopsies important for accurate diagnosis.

A woman with X-linked chronic granulomatous disease developed lupus-like skin lesions, improved with treatment, suggesting a unique skin condition in carriers.